2025
Top advances of the year: Small cell lung cancer
Shields M, Chiang A, Byers L. Top advances of the year: Small cell lung cancer. Cancer 2025, 131: e35770. PMID: 40040254, DOI: 10.1002/cncr.35770.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerExtensive-stage small cell lung cancerCell lung cancerLung cancerLimited-stage small cell lung cancerFrequency of disease relapseTiming of immunotherapyCancer-related mortalityLong-term survivalAntibody-drug conjugatesNeuroendocrine subtypeDisease relapseAggressive biologyMetastatic spreadInferior outcomesImproved survivalImmunotherapyTherapeutic breakthroughConsolidation treatmentCancerPrecision medicineBiomarker selectionSurvivalLurbinectedinForward-thinking approach
2024
Modern Management of Gastric Neuroendocrine Neoplasms
Kunstman J, Nagar A, Gibson J, Kunz P. Modern Management of Gastric Neuroendocrine Neoplasms. Current Treatment Options In Oncology 2024, 25: 1137-1152. PMID: 39083164, DOI: 10.1007/s11864-024-01207-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsG-NENsGastrin-secreting tumorsSurgical resectionHeterogeneous group of tumorsProton pump inhibitor usageResection of visible lesionsG-NEN patientsGroup of tumorsRisk of progressionHigh-risk lesionsMetastatic diseaseNeuroendocrine tumorsNeuroendocrine neoplasmsMetastatic spreadEndoscopic resectionEndoscopic surveillanceTreatment paradigmInhibitor usageNeuroendocrine diseaseResectionTumorLow riskVisible lesionsHeterogeneous groupDe-Escalation
2023
Case Study #8: Alpha-Therapy with Radium-223 Dichloride for Metastatic Castration-Resistant Prostate Cancer
Pasquini L, Morris M. Case Study #8: Alpha-Therapy with Radium-223 Dichloride for Metastatic Castration-Resistant Prostate Cancer. 2023, 387-405. DOI: 10.1007/978-3-031-39005-0_19.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate cancerRadium-223Radiopharmaceutical therapyTreatment of metastatic castration-resistant prostate cancerMinimal bone marrow toxicityRadium-223 dichlorideVisceral metastatic diseaseBone marrow toxicityNearby cancer cellsBone painMarrow toxicityMetastatic diseaseOverall survivalCombination therapyMetastatic spreadBone involvementAlpha therapyClinical developmentTreatment strategiesPalliative effectCancer cellsCancerBoneTransforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib
Roberts C, Rojas-Alexandre M, Hanna R, Lin Z, Ratner E. Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib. Cancers 2023, 15: 3919. PMID: 37568736, PMCID: PMC10417836, DOI: 10.3390/cancers15153919.Peer-Reviewed Original ResearchEpithelial ovarian cancerRepair gene expressionPARP inhibitorsHomologous recombinationGene expressionDNA repair gene expressionCancer cellsLethal gynecologic malignancyDrug-resistant recurrenceDownregulation of genesOvarian cancer cellsGrowth factor betaWild-type cancer cellsDose-dependent mannerDNA repair genesGynecologic malignanciesMesenchymal tumorsOvarian tumorsEpithelial cell lineOvarian cancerMetastatic spreadClinical utilityEOC cellsFunctions of EMTFactor betaType 2 Dendritic Cells Orchestrate a Local Immune Circuit to Confer Antimetastatic Immunity
Weizman O, Luyten S, Krykbaeva I, Song E, Mao T, Bosenberg M, Iwasaki A. Type 2 Dendritic Cells Orchestrate a Local Immune Circuit to Confer Antimetastatic Immunity. The Journal Of Immunology 2023, 210: 1146-1155. PMID: 36881866, PMCID: PMC10067787, DOI: 10.4049/jimmunol.2200697.Peer-Reviewed Original ResearchConceptsType 2 dendritic cellsMetastatic burdenImmune circuitsDendritic cellsConventional type 2 dendritic cellsSyngeneic murine melanomaNK cell compartmentImmune cell responsesColon cancer modelEarly metastatic seedingMetastatic controlTranscription factor IRF3DC populationsNK cellsProinflammatory cytokinesNucleic acid sensingPrimary tumorEffector responsesMetastatic spreadDisease outcomeIntracardiac injectionT cellsInitial immunityTissue-specific ablationCancer model
2022
Importance of tumor subtypes in cancer imaging
Khader A, Braschi-Amirfarzan M, McIntosh LJ, Gosangi B, Wortman JR, Wald C, Thomas R. Importance of tumor subtypes in cancer imaging. European Journal Of Radiology Open 2022, 9: 100433. PMID: 35909389, PMCID: PMC9335388, DOI: 10.1016/j.ejro.2022.100433.Peer-Reviewed Educational MaterialsInfiltrative Disease of the Tubulointerstitium
Aklilu A, Luciano R. Infiltrative Disease of the Tubulointerstitium. 2022, 231-241. DOI: 10.1007/978-3-030-93438-5_18.Peer-Reviewed Original ResearchInfiltrative diseasePlasma cell disordersRenal cell carcinomaRenal tubular cellsWhite blood cellsCancer-targeted therapyKidney injuryPrimary malignancySecondary inflammationTubular damageTubulointerstitial nephritisBronchogenic carcinomaInfiltrative lesionsLymphoproliferative disordersCell carcinomaMetastatic spreadBreast cancerPrimary involvementNormal kidneySolid cancersCell disordersTubular cellsTubular lumenBlood cellsDisease
2021
Prostate Cancer Dormancy and Reactivation in Bone Marrow
Singh D, Patel V, Oh W, Aguirre-Ghiso J. Prostate Cancer Dormancy and Reactivation in Bone Marrow. Journal Of Clinical Medicine 2021, 10: 2648. PMID: 34208521, PMCID: PMC8234151, DOI: 10.3390/jcm10122648.Peer-Reviewed Original ResearchDisseminated cancer cellsProstate cancerTumor microenvironmentCancer cellsBone marrowTarget prostate cancer cellsProstate cancer dormancyVariable clinical coursePrimary tumor microenvironmentProstate cancer cellsMetastatic spreadClinical courseEventual metastasisMalignant phaseCancer dormancyMetastatic cellsPrimary siteProstatePre-cancerousEpigenetic reprogrammingCancerMetastasisSecondary organsDisease statesMarrowA Novel Treatment for Metastatic Serous Cystadenocarcinoma Using a Microwave Ablation: Case Report and Review of the Literature.
Murtha TD, Cornman-Homonoff J, Ayyagari R, Zhang X, Salem RR. A Novel Treatment for Metastatic Serous Cystadenocarcinoma Using a Microwave Ablation: Case Report and Review of the Literature. Pancreas 2021, 50: 434-440. PMID: 33835976, DOI: 10.1097/mpa.0000000000001785.Peer-Reviewed Case Reports and Technical NotesConceptsSerous cystadenocarcinomaSerous cystadenomaMicrowave ablationRecurrence 3 yearsSolitary hepatic metastasisEffective treatment optionPercutaneous microwave ablationPancreatic cystic neoplasmsRare malignant variantDistal pancreatectomyHepatic metastasesPatient factorsPercutaneous ablationCystic neoplasmsTreatment optionsCase reportMetastatic spreadMalignant variantAbdominal visceraLocal invasionNovel treatmentsCystadenomaHepatic implantsAdjacent structuresCystadenocarcinoma
2020
Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
Collins D, Sundar R, Constantinidou A, Dolling D, Yap T, Popat S, O’Brien M, Banerji U, de Bono J, Lopez J, Tunariu N, Minchom A. Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. BMC Cancer 2020, 20: 1210. PMID: 33298007, PMCID: PMC7724793, DOI: 10.1186/s12885-020-07662-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsBrain NeoplasmsClinical Trials, Phase I as TopicCombined Modality TherapyDiagnostic ImagingFemaleHumansKaplan-Meier EstimateLiver NeoplasmsLung NeoplasmsMaleMesothelioma, MalignantMiddle AgedPeritoneal NeoplasmsPleural NeoplasmsProportional Hazards ModelsRetrospective StudiesConceptsDistant metastasisPeritoneal metastasisMPM patientsTreatment paradigmCohort of MPM patientsFrequency of distant metastasesIncidence of bone metastasesPresence of distant metastasesPattern of metastatic spreadDistant metastatic diseaseDistant metastatic disseminationBackgroundMalignant pleural mesotheliomaPresence of symptomsIncidence of boneMetastatic diseaseMetastatic sitesBone metastasesOverall survivalMetastatic spreadContralateral lungPrognostic implicationsMetastatic disseminationRadiological investigationsRetrospective studyPleural mesotheliomaLassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response
van den Pol A, Zhang X, Lima E, Pitruzzello M, Albayrak N, Alvero A, Davis J, Mor G. Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response. Virology 2020, 555: 44-55. PMID: 33453650, PMCID: PMC8451984, DOI: 10.1016/j.virol.2020.10.009.Peer-Reviewed Original ResearchConceptsOvarian cancer cellsHuman ovarian cancer cellsLong-term survivalOvarian cancerCancer cellsTreatment of immunocompetent miceKill ovarian cancer cellsMouse ovarian cancer cellsTreatment of ovarian cancerAnti-tumor responsesImmunocompromised nude miceOncolytic actionImmunocompetent miceMetastatic spreadChemotherapeutic paclitaxelFemale cancersPoor survivalNude miceIntraperitoneal injectionCancer growthSurvival extensionVesicular stomatitis virusVSV glycoproteinCancerReduced neurotropismLiver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors
Kim J, Zimmerman M, Hong J. Liver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors. Journal Of Gastrointestinal Oncology 2020, 11: 601-608. PMID: 32655939, PMCID: PMC7340808, DOI: 10.21037/jgo.2019.11.03.Peer-Reviewed Original ResearchPost-OLT outcomesOrthotopic liver transplantationNeuroendocrine tumorsLiver metastasesLiver transplantationTreatment of unresectable hepatic metastasesPatients of neuroendocrine tumorsRecurrence-free patient survivalUnresectable hepatic metastasesPrediction of survival outcomesPrimary neuroendocrine tumorsUnresectable liver metastasesReview patient selection criteriaLiver neuroendocrine tumorsRate of recurrencePatient selection criteriaHepatic metastasesPrognostic factorsRare neoplasmsPost-OLTDefinitive treatmentMetastatic spreadSurvival outcomesPatient survivalMultiple tumorsEfficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.
Shore N, Armstrong A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Lee H, Haas G, Stenzl A. Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses. Journal Of Clinical Oncology 2020, 38: 5547-5547. DOI: 10.1200/jco.2020.38.15_suppl.5547.Peer-Reviewed Original ResearchRadiographic progression-free survivalEfficacy of enzalutamideAndrogen deprivation therapyMetastatic hormone-sensitive prostate cancerSymptomatic skeletal eventsSoft tissue metastasesMetastatic spreadVisceral metastasesSecondary endpointsBone metastasesFirst symptomatic skeletal eventHormone-sensitive prostate cancerProstate-specific antigen progressionLarge patient subgroupPrior docetaxel treatmentProgression-free survivalSecondary endpoint measuresGreater relative efficacyNew antineoplastic therapiesM0 patientsDeprivation therapyPrimary endpointSkeletal eventsCastration resistanceDisease volumeConventional type 2 dendritic cells and natural killer cells mediate control of early metastatic seeding
Weizman O, Krykbaeva I, Bosenburg M, Iwasaki A. Conventional type 2 dendritic cells and natural killer cells mediate control of early metastatic seeding. The Journal Of Immunology 2020, 204: 88.17-88.17. DOI: 10.4049/jimmunol.204.supp.88.17.Peer-Reviewed Original ResearchConventional type 2 dendritic cellsType 2 dendritic cellsImmune cellsMetastatic burdenNK cellsDendritic cellsIntracardiac injectionHost anti-tumor immunityType I IFN-independent mannerAdaptive immune cellsAnti-tumor immunityLocal immune cellsNatural killer cellsSyngeneic mouse modelIFN-independent mannerEarly metastatic seedingMetastatic controlTranscription factor IRF3Killer cellsPrimary tumorMetastatic spreadInnate sensorsMouse modelMetastatic growthMetastatic seeding
2018
Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma
Cadamuro M, Brivio S, Mertens J, Vismara M, Moncsek A, Milani C, Fingas C, Cristina Malerba M, Nardo G, Dall'Olmo L, Milani E, Mariotti V, Stecca T, Massani M, Spirli C, Fiorotto R, Indraccolo S, Strazzabosco M, Fabris L. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. Journal Of Hepatology 2018, 70: 700-709. PMID: 30553841, PMCID: PMC10878126, DOI: 10.1016/j.jhep.2018.12.004.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBile Duct NeoplasmsCancer-Associated FibroblastsCell Line, TumorCholangiocarcinomaDisease Models, AnimalEndothelial CellsHeterograftsHumansImatinib MesylateLiverLymphangiogenesisLymphokinesMaleMiceMice, SCIDMyofibroblastsPlatelet-Derived Growth FactorProtein Kinase InhibitorsRatsRats, Inbred F344Receptor, Platelet-Derived Growth Factor betaVascular Endothelial Growth Factor AVascular Endothelial Growth Factor CConceptsCancer-associated fibroblastsLymphatic endothelial cellsCholangiocarcinoma specimensMetastatic spreadStromal reactionLiver myofibroblastsGrowth factorExtensive stromal reactionLymph node metastasisEarly metastatic spreadLevels of VEGFBH3 mimetic navitoclaxPlatelet-derived growth factorRole of PDGFVascular growth factorsTumor-associated lymphangiogenesisVEGF-C secretionTransendothelial electric resistanceCholangiocarcinoma invasivenessHuman lymphatic endothelial cellsCurative therapyNode metastasisBiliary treeEarly metastasisPDGFRβ inhibitorOn the Dual Role of Carcinoembryonic Antigen‐Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies
Calinescu A, Turcu G, Nedelcu RI, Brinzea A, Hodorogea A, Antohe M, Diaconu C, Bleotu C, Pirici D, Jilaveanu LB, Ion DA, Badarau IA. On the Dual Role of Carcinoembryonic Antigen‐Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies. Journal Of Immunology Research 2018, 2018: 7169081. PMID: 30406153, PMCID: PMC6204181, DOI: 10.1155/2018/7169081.Peer-Reviewed Original ResearchConceptsCarcinoembryonic antigen-related cell adhesion molecule 1Cell adhesion molecule-1Adhesion molecule-1Molecule-1Role of CEACAM1Progression of malignancyPotential new molecular targetsNew molecular targetsPrognostic factorsSpecific cancer therapyPoor prognosisMetastatic spreadSolid cancersCarcinoembryonic antigenTumor progressionCarcinoembryonic antigen familyHuman malignanciesAntigen familyMolecular targetsCancer therapyBiologic functionsConsiderable downregulationMalignancyTumor suppressorEarly phaseCell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival
Gast CE, Silk AD, Zarour L, Riegler L, Burkhart JG, Gustafson KT, Parappilly MS, Roh-Johnson M, Goodman JR, Olson B, Schmidt M, Swain JR, Davies PS, Shasthri V, Iizuka S, Flynn P, Watson S, Korkola J, Courtneidge SA, Fischer JM, Jaboin J, Billingsley KG, Lopez CD, Burchard J, Gray J, Coussens LM, Sheppard BC, Wong MH. Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Science Advances 2018, 4: eaat7828. PMID: 30214939, PMCID: PMC6135550, DOI: 10.1126/sciadv.aat7828.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkers, TumorCarcinoma, Pancreatic DuctalCell FusionCell Line, TumorCell SurvivalEpithelial CellsFemaleGreen Fluorescent ProteinsHumansHybrid CellsKaryotypingMacrophagesMaleMice, Inbred C57BLMice, TransgenicNeoplastic Cells, CirculatingPancreatic NeoplasmsTumor MicroenvironmentXenograft Model Antitumor AssaysConceptsNeoplastic cellsNumerous neoplastic cellsHuman cancer patientsUrgent medical needPotential therapeutic targetTumor-bearing miceLate-stage progressionHigh lethality rateFuels tumor progressionIdentification of biomarkersOverall survivalDisease stagePeripheral bloodCancer patientsTumor stagingMetastatic spreadNovel biomarkersTherapeutic targetBiologic mechanismsSolid tumorsMedical needMetastatic behaviorTumor progressionCancer highlightLethality rate
2017
Clinical and molecular characterization of patients with cancer of unknown primary in the modern era
Varghese A, Arora A, Capanu M, Camacho N, Won H, Zehir A, Gao J, Chakravarty D, Schultz N, Klimstra D, Ladanyi M, Hyman D, Solit D, Berger M, Saltz L. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. Annals Of Oncology 2017, 28: 3015-3021. PMID: 29045506, PMCID: PMC5834064, DOI: 10.1093/annonc/mdx545.Peer-Reviewed Original ResearchConceptsNext-generation sequencingOverall survivalCUP patientsTargeted therapyPattern of metastatic spreadTargeted Next-Generation SequencingMedian overall survivalMolecular characterization of patientsDiagnosis of CUPInstitutional review board approvalTargetable genomic alterationsTumor molecular profilingDominant mutational signatureTreatment of patientsReview board approvalCharacterization of patientsClinical trial enrollmentDocument demographic informationCytotoxic chemotherapyDismal prognosisMetastatic spreadDescription of patientsPathological evaluationClinical outcomesBoard approvalPancreatic Neuroendocrine Tumors
Klöppel G, Klimstra D, Hruban R, Adsay V, Capella C, Couvelard A, Komminoth P, La Rosa S, Ohike N, Osamura R, Perren A, Scoazec J, Rindi G. Pancreatic Neuroendocrine Tumors. Advances In Anatomic Pathology 2017, 22: 233-239. DOI: 10.1097/pcr.0000000000000211.Peer-Reviewed Original ResearchHistological differentiationProliferative activityWorld Health Organization classificationDegree of histological differentiationTumor grade 3Pancreatic neuroendocrine tumorsTNM staging systemPancreatic neuroendocrine carcinomaPancreatic neuroendocrine tumor grade 3Pancreatic neuroendocrine neoplasmsMeasure of proliferationNeuroendocrine carcinomaNeuroendocrine tumorsNeuroendocrine neoplasmsPrognostic significanceMetastatic spreadOrganization classificationIndividual tumorsTumor biologyGrade 3Staging systemTreatment optionsTumor growthTumorGrading systemColorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions
Zarour LR, Anand S, Billingsley KG, Bisson WH, Cercek A, Clarke MF, Coussens LM, Gast CE, Geltzeiler CB, Hansen L, Kelley KA, Lopez CD, Rana SR, Ruhl R, Tsikitis VL, Vaccaro GM, Wong MH, Mayo SC. Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions. Cellular And Molecular Gastroenterology And Hepatology 2017, 3: 163-173. PMID: 28275683, PMCID: PMC5331831, DOI: 10.1016/j.jcmgh.2017.01.006.Peer-Reviewed Original ResearchColorectal cancerHigh-risk patient cohortEarly detectionEffective prognostic indicatorTreatment of patientsTumor immune therapyNew therapeutic regimensColorectal tumor biologyCurative resectionIntrahepatic recurrenceRecurrent diseaseSystemic therapyTreatment toxicityLiver metastasesImmune therapyTreatment regimensPrognostic indicatorTherapeutic regimensCancer carePatient cohortMetastatic spreadTreatment responseHigh riskPrognostic studiesPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply